knowledge -WSS

knowledge

author：fashion 2025-09-30 08:45:49 - browse：6

Ionis Pharmaceuticals, a California biotech that has spearheaded the development of RNA-targeting medicines, announced on Tuesday that its drug against familial chylomicronemia syndrome, a rare and serious disease that prevents the body from breaking down fats, succeeded in a late-stage clinical trial.

The Phase 3 trial, dubbed Balance, enrolled 66 adults who were randomly divided into three groups and given a monthly injection of placebo or one of two doses of olezarsen, the company’s experimental drug. Treatment with the higher dose of the therapy significantly lowered triglycerides in the blood of those on the drug for six months compared to participants given placebo, though a lower dose did not have this effect. Participants on the high dose didn’t have any instances of painful inflammation of the pancreas, one of the disease’s most serious symptoms, while there were 11 such episodes among those on placebo.

Researchers reported that the treatment was also generally safe, with fewer adverse events among those on olezarsen than among the placebo group.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Apple is now the first public company to be valued at $3 trillion
Next article： Readout Newsletter: Raw milk, Wegovy tests, Eisai and Biogen

WSS

Oak Street deal isn't the answer to health care's woes

Virginia high school admissions case could be legal follow

Supreme Court strikes down use of affirmative action

Ripples from Flovent's discontinuation is killing children with asthma

Free medical tuition alone isn't enough to close gaps in primary care

Hepatitis C has a cure — but many Americans still lack access to it

explore

knowledge

hotspot

Medical leaders decry Supreme Court decision on affirmative action

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Tori Bowie and the unacceptable rates of Black maternal death

Readout Newsletter: Biogen, Ionis, Johnson & Johnson news

Trump demands the U.S. pay no more for drugs than other countries … again

Abbott's new stent may help patients with peripheral artery disease

How to save PrEP access — and even expand it

Why H5N1 bird flu is keeping the CDC's top flu scientist awake

Sports medicine is finally prioritizing gender equality

Ripples from Flovent's discontinuation is killing children with asthma

explore

CVS is willing to dump 10% of its Medicare Advantage members

Medical records are filled with copy

Boston hospital trains restaurant workers on naloxone for overdoses

George Santos makes 1st court appearance after pleading not guilty to 13 counts

United colonoscopy coverage change 'may cost lives,' doctors say

HHS suspends federal funding for EcoHealth Alliance

hotspot

hotspot

explore

Wikipedia